ERAS - Erasca, Inc.
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank $9.25 (-48%) on April 28, 2026 after the company announced that it is facing a legal challenge to intellectual property claims for its lead product candidate (ERAS-0015). The challenge is being waged by competitor Revolution Medicines (RevMed) and relates to RevMed's RMC-6236.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca's ERAS-0015 (Erasca.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Erasca (ERAS) To Contact Him Directly To Discuss Their Options
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank $9. 25 (-48%) on April 28, 2026 after the company announced that it is facing a legal challenge to intellectual property claims for its lead product candidate (ERAS-0015).
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank $9.25 (-48%) on April 28, 2026 after the company announced that it is facing a legal challenge to intellectual property claims for its lead product candidate (ERAS-0015). The challenge is being waged by competitor Revolution Medicines (RevMed) and relates to RevMed's RMC-6236.
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Erasca NASDAQ: ERAS executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal cancers during a Bank of America biotech conference session.
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS PR Newswire
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Erasca (ERAS) To Contact Him Directly To Discuss Their Options
Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca's ERA.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
I initiate Erasca (ERAS) with a "Hold" rating due to promising phase 1 ERAS-0015 data but significant risks. ERAS-0015 showed high ORR in KRAS-mutant NSCLC [64%] and PDAC [50%] at RDE but faces safety and patent litigation risks. Company has strong cash reserves, global rights to ERAS-0015, and a Merck supply collaboration agreement for combination trials.
Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents